Histogen Announces $4.75 Million Private Placement
SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class...
Month: March 2022
Synthetic Biologics Announces Management Transitions in Support of Strategic Transformation
-Frank Tufaro, Ph.D., appointed as Chief Operating Officer of Synthetic Biologics, transitioning from Chief Operating Officer of VCN Biosciences- -Manel...
Progressive Care Announces 2021 Audited Financial Report Conference Call and Investor Update on March 28, 2022
Progressive Care is pleased to announce that the Company has scheduled an investor conference call at 4:30 PM ET on...
Vallon Pharmaceuticals to Participate at the 5th Annual Neuroscience Innovation Forum
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel, today, March 23rdat 9:00...
Springs Rejuvenation, Inc. is Proud to Have Helped AEW Superstar Brian Cage Return to Ring Rapidly
Brian Cage Brian CageATLANTA, GA , March 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Avra, Inc. (OTC PINK: SPRJ),...
BioSig Announces Closing of Public Offering of Common Stock
Westport, CT, March 23, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology...
Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors
MALVERN, Pa., March 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biotechnology company focused on discovering, developing, and...
AccuStem Sciences, Inc. Announces DTC Eligibility
LONDON and PHOENIX, March 23, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC Pink: ACUT), a life sciences company dedicated...
VitalHub Announces Q4 2021 Conference Call Date
TORONTO, March 23, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) is pleased to announce that...
Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions
Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post...
VectivBio Presents Preclinical Data Supporting Apraglutide for Treatment of Acute Graft-Versus-Host Disease at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation
-- Apraglutide, a next-generation GLP-2 analog, protected against chemotherapy-induced gastrointestinal (GI) damage and improved survival in mouse models of GI...
The Joint Corp. Acquires Northeast Regional Developer Territory
- Expands Corporate Clinic Opportunity in the Northeast Region - SCOTTSDALE, Ariz., March 23, 2022 (GLOBE NEWSWIRE) -- The Joint...
New randomized crossover study shows significant improvements in pulmonary symptoms for patients with total laryngectomy when switching to new product range
The randomized cross-over clinical trial assessed the new Provox® Life™ System for pulmonary rehabilitation and quality of life after total...
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability Results to be presented in an...
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease
100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was...
XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection
Compositions and Methods for Enhancing Anti-Viral TherapiesCALGARY, Alberta, March 23, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the...
Roche donates additional medicines and diagnostics for Ukraine
Basel, 23 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the donation of additional medicines and diagnostics...
Immatics Announces Full Year 2021 Financial Results and Corporate Update
IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different solid tumor types in an interim update...
CareDx Announces XenoSure and XenoMap
Represents World’s First Surveillance Solutions for Investigational Use in Xenotransplantation Research and Post-Xenotransplant Clinical MonitoringSOUTH SAN FRANCISCO, Calif., March 23,...
VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update
OVAL top-line data for ofra-vec progression free survival (PFS) primary endpoint expected in 2H 2022; with positive results, VBL anticipates...
